Back

Tyra Biosciences shares plunge 17.66% as Pomerantz investigates investors’ claims

Verifying
  • Pomerantz LLP is investigating Tyra Biosciences and certain officers and directors.
  • Tyra shares fell $4.72, or 17.66%, closing at $22.01 on September 9, 2026.
  • Tyra announced initial SURF302 results for oral dabogratinib in bladder-cancer patients.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.